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Vaccines to efficiently block or limit sexual transmission of both HIV and human papilloma virus (HPV) are urgently needed.
Chimeric virus-like-particle (VLP) vaccines consisting of both multimerized HPV L1 proteins and fragments of SIV gag p27,
HIV-1 tat, and HIV-1 rev proteins (HPV–SHIV VLPs) were constructed and administered to macaques both systemically and
mucosally. An additional group of macaques first received a priming vaccination with DNA vaccines expressing the same SIV
and HIV-1 antigens prior to chimeric HPV–SHIV VLP boosting vaccinations. Although HPV L1 antibodies were induced in all
immunized macaques, weak antibody or T cell responses to the chimeric SHIV antigens were detected only in animals
receiving the DNA prime/HPV–SHIV VLP boost vaccine regimen. Significant but partial protection from a virulent mucosal
SHIV challenge was also detected only in the prime/boosted macaques and not in animals receiving the HPV–SHIV VLP
vaccines alone, with three of five prime/boosted animals retaining some CD4 T cells following challenge. Thus, although
some immunogenicity and partial protection was observed in non-human primates receiving both DNA and chimeric
HPV–SHIV VLP vaccines, significant improvements in vaccine design are required before we can confidently proceed withINTRODUCTION
An HIV vaccine is urgently needed to prevent the
millions of new HIV infections each year occurring pri-
marily in underdeveloped countries (Piot et al., 2001).
Most HIV infections occur across the genital mucosa
and vaccines that block or limit mucosal transmission
are likely to be the most efficient vaccines. Vaccines
delivered via mucosal surfaces appear most effective at
the induction of mucosal immunity (Lehner et al., 1999).
Although prevention of HIV transmission might most
effectively occur by the induction of high-titer neutralizing
antibodies, safe or viable HIV vaccine strategies have
not to date induced antibodies capable of neutralizing
diverse field strains of HIV-1 (Lacasse et al., 1999). There
is, however, a large body of evidence that HIV-1 or SIV
specific T cells can dramatically curtail viral replication,
in some cases sufficiently to render the virus nonpatho-
genic for considerable periods in vivo (Amara et al., 2001;
Koup et al., 1994; Rosenberg et al., 2000).
The induction of specific T cells by vaccines requires
the presentation of specific peptides from within host
cells. The entry of vaccine constructs into host cells
greatly facilitates this process. Vaccine approaches ca-
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176pable of inducing HIV or SIV specific T cells include
plasmid DNA vaccines, live vector vaccines, virus-like
particle (VLP) vaccines, and live attenuated vaccines
(Barouch et al., 2000; Davis et al., 2000; Kent et al., 2001b,
1998). Live attenuated vaccines are generally considered
too dangerous to enter human clinical trials at present
(Baba et al., 1995; Kent et al., 2001b). DNA and live-
vectored vaccines are by themselves relatively inefficient
at induction of specific T cells; although when utilized
together with cytokines or sequentially in prime/boost
approaches DNA and live-vector vaccines induce high
levels of HIV or SIV specific T cells and nonsterilizing
protective immunity (Amara et al., 2001; Barouch et al.,
2000). Nonreplicative VLP vaccines could be among the
safest of these vaccine approaches and, if the vaccines
efficiently enter host cells, could induce or boost HIV or
SIV specific T cells.
Human papilloma virus (HPV) causes anogenital warts
and cervical cancer and there is also an urgent require-
ment for the development of an HPV vaccine (Frazer,
1996; Galloway, 1998; Schiller and Lowy, 2001). HPV VLPs
can be generated by expressing the HPV capsid protein
L1 utilizing baculovirus or other expression systems
where five L1 subunits multermerize into immunogenic
pentamers and 72 L1 pentamers multimerize into a HPV
VLP (Kirnbauer et al., 1992; Peng et al., 1998; Zhou et al.,this approach to clinical trials. © 2002 Elsevier Science (USA)
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1991). HPV L1 VLPs are efficiently taken up by bothke-part
mucosal epithelial cells and antigen-presenting cells (Liu
et al., 1998). HPV L1 VLPs have shown promise in mouse
and rabbit papillomavirus models, where they are capa-
ble of inducing mucosal antibody and T cell responses
when delivered mucosally, as well as providing protec-
tion from papillomavirus challenge (Liu et al., 1998; Revaz
et al., 2001). HPV VLPs have been shown to be immuno-
genic in small human trials and have entered ex-
panded human clinical trials for the prevention and treat-
ment of cervical cancer and anogenital warts (Zhang et
al., 2000).
The L1 protein of HPV can be modified to express
small (up to 60 aa) portions of additional proteins by
deleting the coding sequence for the L1 C-terminal 25 aa
and adding the foreign gene to generate a safe mucosal
delivery vector. The resultant chimeric HPV VLPs can
induce CTLs in murine systems, including to HIV-1
epitopes, and provide protection against tumor chal-
lenge models (Liu et al., 1998; Peng et al., 1998). The
prospect emerges that an effective chimeric HIV–HPV
VLP vaccine could be delivered mucosally to induce
immunity against two important sexually transmitted
pathogens, HPV and HIV.
A robust model in which to evaluate the efficacy of
candidate mucosal HIV vaccine approaches is a patho-
genic simian–human immunodeficiency virus (SHIV) in-
fection administered to the rectal mucosa of outbred
monkeys (Amara et al., 2001; Barouch et al., 2000; Li et
al., 1992). SHIV is a chimeric primate lentivirus virus
utilizing an SIV backbone with the HIV-1 env, tat, and rev
genes replacing the SIV env, tat, and rev genes. The
SHIV genes we chose to express in the HPV–HIV chi-
meric VLP vaccines were: (a) HIV-1 tat and rev, since
these are small genes more readily expressed in chi-
meric HPV VLPs, expressed early in the infection cycle,
thereby potentially inducing CTLs which can clear infec-
tions prior to the formation of progeny virus, shown to be
important targets for CTL responses (Addo et al., 2001;
Allen et al., 2000a) and could be subsequently studied in
human clinical trials if found effective and (b) SIV gag
p27, since this portion of the virus is conserved, an
important target for both CTLs and T-helper responses
(Gauduin et al., 1999), and we had previous experience in
evaluating SIV gag specific T cell responses in ma-
caques (Kent et al., 2001b, 1996).
We evaluated HPV–HIV VLPs for immunogenicity and
protective immunity using a mucosal SHIV challenge
model in macaques. Since we and others have previ-
ously shown that DNA priming followed by attenuated
poxvirus boosting can induce high levels of HIV-1 or SIV
specific T cells and protection from viral challenge in
macaques (Allen et al., 2000b; Amara et al., 2001; Hanke
et al., 1999; Kent et al., 1998), we also evaluated a DNA
vaccine prime and HPV–HIV VLP boost approach to
determine whether this approach could efficiently induce
T cell mediated immunity in macaques.
RESULTS
Vaccinations
HPV–SHIV chimeric vaccines expressing all of HIV-1
tat (2 products, HPV6bL1/tat1, HPV6bL1/tat2), HIV-1 rev (3
products, HPV6bL1/rev1, HPV6bL1/rev2, HPV6bL1/rev3),
and part of SIV p27 gag (HPV6bL1SIVp27c and
HPV6bL1SIVp27d, spanning amino acids 91–188, 43% of
the SIVp27 gag protein) were constructed and induced
anti-HPV L1 antibodies in mice with 1 g of the construct
delivered twice IM without adjuvant (Liu et al., manu-
script in preparation). Five separate SIV p27 HPV VLPs
were constructed, but only two (p27c and p27d con-
structs) induced anti-HPV L1 antibodies in mice and
were included in this study (Liu et al., manuscript in
preparation). Of the seven constructs immunogenic in
mice, three (tat1 and tat2 and rev3) were shown to form
VLPs and the other four constructs formed chimeric pen-
tamers by electron microscopy. The combination of
seven immunogenic HPV–SHIV VLPs was administered
to macaques three times by both IM and intrarectal
routes (Fig. 1, VLP only).
The group of five macaques receiving the DNA prime
and HPV–SHIV VLP boost vaccine regimen received
three separate DNA vaccines expressing HIV-1 tat, rev,
and SIV gag. The SIV gag vaccine was codon optimized
for expression in mammalian cells (Egan et al., 2000;
FIG. 1. Vaccination and challenge schedule. DNA and chimeric HPV–SHIV VLP vaccines were administered at the times noted.
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Shiver et al., 2002). The expression of HIV-1 tat vaccine
was driven from a CMV promoter and showed high
levels of functional activity in vitro and in macaques (Kent
et al., 2001a). The HIV-1 rev DNA vaccine was expressed
off a RSV promoter and showed high levels of functional
activity in vitro, inducing a 44-fold increase in rev activity
from the pDM128 CAT-RRE reporter relative to mock
control. The DNA vaccines were administered both IM
(500 g) in saline and epidermally via gene gun (15 g)
twice (Fig. 1, prime boost). All vaccines were well toler-
ated by the macaques.
Antibody responses to HPV and SHIV antigens
following vaccinations
Both anti-HPV and anti-SHIV antibody responses were
assessed in plasma prior to and following vaccinations.
All 15 macaques received HPV VLP vaccinations, with
the control macaques receiving nonchimeric HPV VLPs.
HPV L1 specific antibodies were increased in each indi-
vidual macaque and across all groups following the HPV
VLP vaccinations (Fig. 2). SIV gag, HIV-1 tat, and HIV-1
antibody responses were evaluated by EIA, using recom-
binant proteins as antigens and reference antibodies or
SIV-positive sera as positive control responses. No sig-
nificant anti-SHIV antibody responses were detected by
EIA in sera from any of the animals, although responses
were readily detected in reference HIV-1 tat, HIV-1 rev,
and SIV antibodies (Fig. 3A). Anti-SIV gag responses
were also assessed by Western blot using cross-reactive
HIV-2 antigens. Weak anti-gag bands were detected in
three of five animals receiving the DNA vaccine prime/
HPV–SHIV VLP vaccine boost vaccine regimen, but in
none of the HPV–SHIV VLP vaccinated animals nor in
controls (Fig. 3B and data not shown). The anti-gag
responses detected by Western blot in a subset of DNA
prime/HPV–SHIV VLP boost vaccinated animals recog-
nized both p27 and p17 gag antigens (Fig. 3B), suggest-
ing that the antibody response was primarily recognizing
the entire gag protein expressed by the pSIVoptgag DNA
vaccine rather than the fragment of p27 expressed by the
chimeric HPV–SIVp27 VLPs.
Lymphoproliferative responses following vaccinations
To assess the CD4 T cell immunogenicity of the
vaccinations, lymphoproliferative assays were per-
formed using freshly isolated PBMC stimulated by anti-
gens expressed by the vaccines (Fig. 4A). Prior to vac-
cination there were no lymphoproliferative responses to
SIV gag antigens and a mitogenic response was present
in all animals. Following either HPV–SHIV VLP vaccines
alone or the DNA prime/HPV–SHIV VLP boost vaccine
regimen there were no significant lymphoproliferative
responses to vaccine antigens. Using identical or similar
SIV or HIV-1 antigens in recent or concurrent live atten-
uated vaccine studies or DNA prime/fowlpoxvirus boost
vaccine studies, lymphoproliferative responses with
stimulation indices of 5–20 have been observed in vac-
cinated pigtail macaques (Kent et al., 1997, 1998, 2000,
and Kent et al., unpublished data).
IFN ELISPOT responses following vaccinations
Antigen specific production of IFN by T cells was
quantified by ELISPOT assays in response to whole
inactivated SIV and overlapping 15-mer peptides on
batched frozen PBMC performed on the same day. IFN
responses were weak or undetectable following either of
the vaccine regimens and not significantly greater than
responses in animals receiving only control vaccines
(Fig. 4B). In concurrent or recent experiments studying
either live attenuated or DNA prime/fowlpoxvirus boost
vaccinations in Macaca nemestrina, antigen specific re-
sponses of up to 650 IFN spot-forming cells/million
PBMC are observed using the same methods and similar
or identical SIV or HIV-1 antigen preparations (Dale et al.,
2000; Kent et al., 2001b, and Kent et al., unpublished
data).
T cell responses by intracellular cytokine staining
To further quantify and phenotype vaccine-induced T
cell responses, antigen specific responses in whole
blood were assessed by intracellular IFN staining and
flow cytometry following a 6-h in vitro culture with either
overlapping peptides or whole inactivated SIV. Weak SIV
specific responses (mean 0.1% of gated lymphocytes)
were detectable only in macaques following the DNA
prime/HPV–SHIV VLP boost vaccine regimen and not in
controls or animals receiving the HPV–SHIV VLP vac-
cines alone (Fig. 5). Differences between DNA prime/
HPV–SHIV VLP boost vaccinated animals and controls of
borderline significance were present to the whole inac-
FIG. 2. Anti-HPV L1 antibodies pre- and postvaccination. HPV L1
antibodies in plasma were measured by EIA at week 0, prior to any
vaccinations, and at week 15, after the animals had received all vac-
cines. Mean (SD) anti-HPV L1 antibodies are shown for the three
groups of five macaques receiving the DNA prime/HPV–SHIV VLP
boost regimen (DNA/VLP), the HPV–SHIV VLP vaccines alone (VLP), or
control HPV VLPs not expressing SHIV antigens (controls).
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tivated SIV antigen (P  0.057, Student’s t test, Fig. 5A).
Although some individual animals appear to be respond-
ing to SIVgag and HIV-1 tat peptides in the prime/boost
group (Figs. 5B and 5C), as a group these responses
were not statistically significant in comparison to the
control group (P  0.08 for SIVgag and P  0.18 for
HIV-1tat). No rev specific responses were detected (Fig.
5D). Responses were approximately equivalent in the
CD3 only and CD3CD8 populations, suggesting
that the responses induced and detectable by this tech-
nique were primarily CD8 T cell responses.
SHIV challenge stock
An HIV-1IIIB-based SHIV strain, SHIV229(mn), previously
shown to be pathogenic in M. nemestrina was kindly
obtained from Dr. Mike Agy, University of Washington,
Seattle, and amplified on M. nemestrina PBMC (Thomp-
son et al., 2000). Prior to the challenge of the vaccinated
animals, the SHIV229(mn) stock was assessed for infectivity
via intrarectal administration in pigtailed macaques at
two doses (2 105 TCID50 in two animals: M21 and M26,
and 4  104 TCID50 in two animals: M24 and M25) as
assessed by serial analyses of peripheral CD4 T cells
by FACS and plasma SHIV RNA levels by real time PCR.
All four inoculated animals had an abrupt loss of CD4
T cells within 3 weeks (Fig. 6A) and had high levels of
SHIV RNA detected, peaking 2 weeks postinoculation
(Fig. 6B).
Outcome of SHIV challenge
The SHIV229(mn) challenge stock was inoculated into all
15 macaques on the same day, 6 weeks after the last
vaccination at a dose of 105 TCID50 intrarectally. CD4 T
cells and plasma SHIV RNA were followed for 12 weeks.
All 5 control macaques had high levels of SHIV RNA at
peak levels at 2 weeks (mean 8.6 log10 copies/ml) fol-
FIG. 3. Anti-SHIV antibody responses following vaccinations. (A) Anti HIV-1 tat, HIV-1 rev, and SIV gag were measured in plasma by EIA. Plasma
was diluted 1 in 50 for the anti HIV-1 tat responses and 1 in 500 for the anti HIV-1 rev and SIV gag responses. Antibody responses prior to vaccination,
after DNA vaccinations only (week 8), and after all vaccinations (week 15) are shown. Mean (SD) responses for each vaccine group of five macaques
are shown. Positive control responses to reference rabbit anti-HIV-1 tat (1 in 1600) and rev (1 in 1600) antibodies and plasma from a SIV-infected
macaque (1 in 100) were OD450 (SD) 2.8  0.3, 2.2  0.1, and 1.2  0.1, respectively. (B) Western blot to HIV-1 antigens pre- (week 0) and
postvaccinations (week 15) in a macaque from each vaccine group. Control human sera negative () and positive () for HIV-2 is shown.
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lowing inoculation and at set point at 8 weeks (mean 6.7
log10 copies/ml) (Fig. 7A). Similarly, all 5 control ma-
caques lost CD4 T cells precipitously, being 4.8% at
week 2 and 0.7% of total lymphocytes by week 8 (Fig. 7C).
The group of 5 macaques receiving the three doses of
HPV–SHIV VLP vaccines alone was not significantly pro-
tected from the SHIV challenge. The mean SHIV RNA
level in this group was 8.4 log10 copies/ml at 2 weeks and
6.4 log10 copies/ml at 8 weeks (Fig. 7B), and the mean
CD4 T cell level was 14.0% at 2 weeks and 1.3% at 8
weeks (Fig. 7D). Interestingly, one of the HPV–SHIV VLP
vaccinated animals, M38, had a slightly lower SHIV RNA
FIG. 4. Anti-SHIV T cell responses to vaccination. A. Lymphoproliferative responses to SHIV antigens. Proliferation of freshly isolated macaque
PBMC to whole inactivated SIV (SIV), SIVp55 gag protein both prior to (week 0) and following all vaccinations (week 15), and overlapping 15-mer HIV-1
rev or tat peptides following vaccinations are shown. Proliferation was assessed by [3H]thymidine incorporation and expressed as stimulation index
of mean counts from active antigen wells/counts from relevant control antigen wells. Mean (SD) responses are shown for the three groups of five
macaques receiving the DNA prime/HPV–SHIV VLP boost vaccine regimen (DNA/VLP), the HPV–SHIV VLP regimen alone (VLP), or control DNA and
HPV VLP vaccinations (Cont). Mean positive control responses to pokeweed mitogen (PWM) in all groups are also shown. B. IFN ELISPOT responses
to SHIV antigens. ELISPOT responses to pools of overlapping 15-mer peptides of SIV gag, HIV-1 tat, and HIV-1 rev were assessed prior to (week 0)
and following (week 15) vaccinations. Macaque IFN ELISPOT responses were evaluated on batched frozen PBMC using a macaque-specific kit and
enumerated using an ELISPOT counter. Mean (SD) responses are shown for the three groups of five macaques receiving the DNA prime/HPV–SHIV
VLP boost vaccine regimen (DNA/VLP), the HPV–SHIV VLP regimen alone (VLP), or control DNA and HPV VLP vaccinations (Cont). Mean positive
control responses to the superantigen Staphylococcal entertoxin B (SEB) in all groups are also shown.
180 DALE ET AL.
level 8 weeks following inoculation and retained some
CD4 T cells (4.8% of total lymphocytes, compared to
preinfection level of 16.4%) out to 12 weeks following
challenge.
The group of five macaques receiving the DNA vac-
cine prime and HPV–SHIV VLP boost vaccine regimen
had SHIV RNA levels that were modestly but significantly
lower than that of the control macaques 2 weeks post-
challenge (mean 7.8 vs 8.6 log10 copies/ml in control
macaques, P  0.03, Student’s t test). The SHIV RNA
levels of the group was not significantly lower by 8
weeks postchallenge (mean 6.4 vs 6.7 log10 copies/ml in
controls). The three DNA vaccine prime and HPV–SHIV
VLP boost vaccinated animals with the lower SHIV RNA
levels at peak and set point (M28, M29, M30) had some
retention of CD4 T cells out to 12 weeks following chal-
lenge. Macaques M28, M29, and M30 had a mean %CD4
T cell level of 11.5% 12 weeks following challenge, com-
pared to 29.7% in these three animals preinfection and
0.9% in the five control animals 12 weeks postchallenge.
As a group, macaques receiving the DNA prime/HPV–
SHIV VLP boost vaccine regimen demonstrated a bor-
derline significant retention of CD4 T cells in compar-
ison to the control group (7.0% vs 0.9% at week 12, P 
0.056).
DISCUSSION
This study examined the immunogenicity and protec-
tive efficacy of chimeric HPV–SHIV VLP vaccines, ex-
pressing SIV p27 gag and the regulatory proteins HIV-1
tat and rev, delivered both mucosally and systemically in
macaques. Very limited immunogenicity was detected
following vaccination, even when the HPV–SHIV VLP
vaccination was preceded by a DNA vaccine prime en-
coding the same SHIV antigens. Weak anti-HPV antibody
FIG. 5. Intracellular IFN expression following vaccinations. One week following all vaccinations, whole blood from the three groups of five
macaques was stimulated with various antigen preparations: whole inactivated SIV (A), overlapping 15-mer SIV gag peptides (B), overlapping 15-mer
HIV-1 tat peptides (C); and overlapping 15-mer HIV-1 rev peptides (D) for 6 h. The proportion of antigen-specific gated lymphocytes expressing IFN
and either CD3 (solid bars) or both CD3 and CD8 (open bars) was assessed by flow cytometry. The mean SD is shown for the three vaccine groups
for each antigen.
181HPV–SHIV VIRUS-LIKE-PARTICLE VACCINES
responses were detected by EIA, suggesting that deliv-
ery of the VLPs was achieved. However, only weak anti-
SIV gag responses were detected by Western blot in a
subset of DNA prime/HPV–SHIV VLP boost vaccinated
animals, and no anti-SHIV responses were detected by
EIA. T cell immunogenicity was also limited with no
anti-SHIV T cell responses detected by lymphoprolifera-
tion or IFN ELISPOT and only weak anti-SIV gag and
HIV-1 tat CD8 T cell responses detected by intracellu-
lar IFN staining, again only in animals receiving the
DNA prime/HPV–SHIV VLP boost vaccine regimen.
Previous experience has demonstrated the enhanced
level of T cell immunogenicity of DNA prime/live vector
boosting vaccination. It might have been expected that, if
the HPV–SHIV VLP vaccines were capable of even
weakly stimulating or boosting T cell responses, the
DNA prime/HPV–SHIV VLP boost vaccine regimen would
have produced detectable levels of T cell immunogenic-
ity by assays such as lymphoproliferative assays and
IFN ELISPOT. The weak anti-SHIV T cell responses
detected by intracellular IFN staining following all vac-
cines could have been stimulated primarily by the DNA
vaccines alone, although this was not directly assessed
at that time point. Taken together, the immunogenicity
results suggest that the HPV–SHIV VLP vaccines studied
were not a highly effective delivery vector for anti-SHIV
immune responses in outbred primates.
A model utilizing known MHC haplotypes and specific
epitopes to detect immune responses (such as inbred
mice or MamuA*01 rhesus macaques) may have been
a more sensitive model in which to detect anti-SHIV T
cell responses. However, given previous experience with
measuring anti-HIV-1 or SIV T cell responses in outbred
primates, and recent or concurrent studies using alter-
nate vaccine strategies which induced anti HIV-1 or SIV
T cell responses, the HPV–SHIV VLP vaccine regimens
do not appear highly T cell immunogenic (Kent et al.,
2001b, 1998). The significant differences in T cell immu-
nogenicity observed between previous inbred murine
studies of chimeric HPV–HIV VLP vaccines (Peng et al.,
1998; Liu et al., 2000) and this outbred macaque study
were remarkable. At least two reasons may explain the
weak immune responses. First, only three of seven chi-
meric HPV constructs formed VLPs, while the rest were
chimeric pentamers. Although pentamers and chimeric
pentamers are immunogenic at inducing L1 specific an-
tibodies (Yuan et al., 2001; Liu et al., manuscript in prep-
aration), their ability to deliver the incorporated proteins
might be compromised. The incorporated sequences did
not predict protein production levels or the formation of
VLPs (Liu et al., manuscript in preparation). Second, the
absolute amount of each of the capsids/capsomers used
in this study may have been insufficient to deliver the
incorporated proteins to the immune system of the pri-
mates studied and higher doses should be assessed in
future studies. It is also possible that the administration
of multiple HPV L1 VLPs and pentamers limited the
ability of the animals to generate adequate immunity to
the HIV-1 or SIV inserts, although this seems unlikely.
The efficacy of the vaccines was evaluated utilizing a
highly pathogenic mucosal SHIV challenge. The chal-
lenge stock was grown in macaque PBMC and validated
prior to challenge of the vaccinated animals. Animals
receiving the HPV–SHIV VLP vaccine alone were not, as
a group, significantly protected from high plasma SHIV
RNA levels or CD4 T cell loss, although one of the five
animals had a slightly lower SHIV RNA level and stably
retained some CD4 T cells out to 12 weeks following
challenge. Animals receiving the DNA prime/HPV–SHIV
VLP boost vaccine regimen, as a group, had significantly
lower SHIV RNA levels early following SHIV challenge.
Three of the five animals were protected from the rapid
and complete CD4 T cell loss observed in controls out
to 12 weeks following challenge. There was no correla-
tion between the animals that demonstrated weak anti-
SHIV antibody or T cell responses and protection from
SHIV challenge in these groups of five animals (not
shown).
It is of interest that vaccination with the DNA prime/
HPV–SHIV VLP boost regimen was able to provide suf-
ficiently blunted peak SHIV RNA responses to rescue
some CD4 T cells from the acutely pathogenic effects
FIG. 6. Validation of intrarectal SHIV challenge stock. A macaque–
PBMC grown SHIV229(mn) stock was assessed for infectivity via intrarec-
tal administration in pigtailed macaques at two doses (2  105 TCID50
in two animals: M21 and M26, and 4  104 TCID50 in two animals: M24
and M25) as assessed by serial analyses of (A) peripheral CD4 T
cells by flow cytometry and (B) plasma SHIV RNA levels by real-time
PCR.
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of the SHIV challenge. It is possible that additional mu-
cosal immune responses were induced by the regimen
that, together with modest systemic responses, made
this a partially effective vaccine strategy. Alternatively,
the partial protection observed in this group may have
been derived from the DNA vaccines only, similar to
previous observations of SIV and SHIV DNA vaccination
studies in macaques (Barouch et al., 2000; Lu et al.,
1996), although this does not explain the partial protec-
tion observed in one of the HPV–SHIV VLP only immu-
nized animals.
The data also suggest that the SHIV-macaque chal-
lenge model, which although it is highly pathogenic over
2–3 weeks, requires only modest (mean 0.6 log10 cop-
ies/ml difference between vaccinated and control ma-
caques in this study) control of the early virologic profile
to significantly affect the immunologic outcome. This is
consistent with observations in HIV-1 infected humans
where modest (0.5 log10) differences in virologic set point
6–12 months after seroconversion profoundly affect the
time to develop clinical AIDS or death, although the time
frame is much longer (Mellors et al., 1996).
There are substantial improvements that can, and
must, be made to chimeric HPV–HIV VLP vaccines to
improve their immunogenicity and efficacy in primates.
Incorporating additional SHIV antigens into the vaccines
may provide broader protective efficacy in outbred sub-
jects. The incorporation of larger SHIV proteins into
HPV–VLP vaccines will ultimately require novel technol-
ogies as the restriction in the size of the chimeric protein
that can be incorporated into L1 means that it is imprac-
tical to construct and produce large numbers of VLP
vaccines. The HPV L2 capsid protein may be able to
incorporate larger chimeric proteins and more efficiently
form true VLPs. Tethering proteins to the external por-
tions of HPV L1 or L2 VLPs may also be an effective
method to deliver larger proteins, as well as potentially
direct the VLPs to specific cell types. VLPs utilized with
mucosal adjuvants can increase the immunogenicity of
VLPs in mice and this may be required in primates
(Gerber et al., 2001; Greer et al., 2000). Future genera-
tions of chimeric HPV–HIV VLPs may be more effective
and viable mucosal vaccine vectors and proceed to hu-
man trials.
FIG. 7. Outcome of SHIV challenge. All vaccinated and control macaques were challenged intrarectally with SHIV229(mn) and assessed for (A) CD4
T cell loss by FACS and (C) plasma SHIV RNA by real-time PCR. Mean responses of CD4 T cells and SHIV RNA of each vaccine group are shown
in (B) and (D).
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MATERIALS AND METHODS
HPV–SHIV VLP vaccines
Recombinant HPV virus-like particles encoding HIV-1
tat, HIV-1 rev, and SIV p27 gag were produced by ex-
pression of a fusion protein between the L1 protein of
HPV strain 6 and fragments of either SIV P27 gag (two
fragments), HIV-1 tat (2 fragments), or HIV-1 rev (three
fragments) as previously described (Liu et al., 2000, 1998;
Peng et al., 1998). Briefly, a plasmid encoding a C-termi-
nal deleted HPV6b L1 had approximately 150 nucleotide
fragments spanning HIV-1AD8 tat, HIV-1NL4.3 rev, or SIVmac239
p27 gag inserted into the terminal NcoI site. The plas-
mids were transfected into baculovirus using a Bacol-
uGold transfection kit (PharMingen, San Diego, CA) and
VLPs were produced by infection of SF9 cells. The seven
HPV–SHIV VLP vaccines expressing SIVmac239 gag p27
(part), HIV-1AD8 tat, and HIV-1NL4-3 rev were pooled and
administered to two of the three groups of five ma-
caques. HPV–SHIV VLPs were administered intramuscu-
larly (20 g each of the seven constructs [140 g in total]
IM split between left and right quadriceps) as well as
intrarectally (20 g each construct by atraumatic instil-
lation 4 cm into the rectum) three times as noted in Fig.
1. Control macaques received HPV VLPs not containing
SHIV antigens.
DNA vaccines
A mixture of three plasmids, encoding SIVmac239gag
(pSIVoptgag), HIV-1NL4.3 tat (pCMVNLtat), and HIV-1NL4.3rev
(pRSVrev), were pooled and administered to macaques
twice as a priming vaccine to one of the three groups of
five macaques. Five macaques received plasmid pCMV-
empty, not encoding SIV or HIV-1 genes, as a negative
control.
pSIVoptgag, encoding codon optimized SIVmac239 gag,
was a kind gift from Dr. Gwen Heidecker (Merck Re-
search Laboratories, PA) (Egan et al., 2000; Shiver et al.,
2002). Plasmid pCMVNLtat, encoding the HIV-1NL4-3 tat,
was constructed from plasmid vector pEGFP-N1 (Clon-
tech BD Biosciences, CA) by replacing the EGFP coding
sequence with the SalI–BamHI restricted tat fragment
from the cDNA clone pCR2-tat1 as previously described
(Purcell and Martin, 1993). Expression of tat was under
the control of the human cytomegalovirus (CMV) imme-
diate-early promoter. Plasmid pRSVrev was sourced from
Dr. Brian Cullen (Hope et al., 1990b). HIV-1NL4.3 rev ex-
pression was under the control of the rous sarcoma virus
(RSV) promoter.
Functional expression of tat from the construct pCM-
VNLtat was confirmed in vitro by cotransfection of HeLa
cells with pLTR-EGFP plasmid and FACS analysis of
EGFP expression (Kent et al., 2001a). In vivo functional
expression of tat was confirmed by intradermal (gene
gun) coinoculation with pLTR-gal (expressing -galac-
tosidase) in macaques (Kent et al., 2001a). Rev expres-
sion was assessed in vitro by cotransfection of pRSVRev
and the CAT-RRE reporter, pDM128 (Hope et al., 1990a),
into HeLa cells and subsequent measurement of chlor-
amphenicol acetyltransferase activity (Sambrook et al.,
1989).
For each of the three DNA vaccines, plasmid DNA/E.
coli (DH5) was amplified in 2.5 L Luria–Bertani medium
by antibiotic selection. Endotoxin-free plasmid DNA was
purified using the Qiagen Giga kit (Hilden, Germany).
Plasmids pSIVoptgag, pCMVNLtat, and pRSVrev were
combined for IM and epidermal (gene gun) immuniza-
tion. Intramuscular delivery used 500 g of each plasmid
in normal saline, delivering half the vaccine to each of
the right and left quadriceps muscle bundles. Gene gun
immunization used 1 m gold beads coated with a mix-
ture of the three plasmids (1 g each plasmid), delivering
15 shots (15 g/plasmid in total) to shaved lower abdo-
men skin at 350 psi as previously described at the times
shown in Fig. 1 (Kent et al., 2001b, 1998).
Macaques
Colony bred, juvenile (2–4 kg), SRV-D free pigtailed
macaques (M. nemestrina, n  15) were studied. Ani-
mals were sedated with ketamine prior to vaccinations
and procedures, and the relevant animal experimenta-
tion and ethics committees approved the studies.
ELISA assay for HPV L1 specific Ig G antibodies
Measurement of HPV L1 specific IgG antibodies in
serum was performed in flat-bottom polystyrene microti-
ter plates (Maxisorp) as described (Liu et al., 1998).
Briefly, plates were coated with 50 l of nonchimeric
HPV6bL1 VLPs at 10 g/ml in PBS overnight at 4°C and
then blocked with 100 l 5% milk in PBS at 37°C for 1 h.
The plates were washed using 0.5% PBS Tween 20
(PBST) and sera were added. After incubation at 37°C for
1 h, the plates were washed three times with PBST, and
HRP-conjugated goat anti-rhesus IgG (Southern Biotech-
nology, Birmingham, AL) was added at 1:1000 dilutions
and incubated at 37°C for 1 h. A 5-mg OPD tablet (Sigma)
was dissolved in 12.5 ml H2O with 4 l H2O2. Substrate
(50 l) was added and the reaction was stopped with 3
N HCl, and plates were read at 495 nm using a Bio-Rad
4500 reader.
ELISA for SIV gag, HIV-1 tat, and rev specific IgG
antibodies
Specific antibodies against vaccine antigens were an-
alyzed post DNA and HPV immunizations. Antigens SIV-
gag, HIV-1tat, and HIV-1rev were obtained through the
AIDS Research and Reference Reagent Program (NIAID,
NIH). Maxisorp immunoplates (Nunc, Roskilde, Den-
mark) were coated with antigen at 1 g/ml in 50 l PBS
overnight at 4°C. Antigen was removed from the wells
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and the wells were washed using three PBST wash
cycles (400 l/well) prior to blocking with 10% skim milk
powder/PBS (200 l/well). Plasma collected from the
macaques prior to immunization, 4 weeks post DNA
immunizations, and 1 week post HPV VLP immunizations
was diluted 1 in 5, 1 in 50, and 1 in 500 (in PBS/1% skim
milk powder) and 100 l was added per well in duplicate.
Plasma was incubated with the antigen-coated wells for
1 h at room temperature. Wells were washed with PBST
as before and HRP-conjugated goat anti-rhesus IgG
(Southern Biotechnology) was added at a dilution of
1:2000 and incubated at room temperature for 1 h. Plates
were washed four times with PBST prior to detection
using TMB peroxidase substrate (Kirkgaard, Gaithers-
burg, MD) and absorbance was read at 450 nm (Titertek).
Polyclonal antibodies against SIV gag (monkey anti SIV
(Kent et al., 2001b)), HIV-1 tat (rabbit anti-HIV-1 tat anti-
body; Intracel Issaquah, WA), and HIV-1 rev (rabbit anti-
HIV-1 rev antibody; Dr. Alan Cochrane, University of To-
ronto) were titrated and used as a positive control for
each assay. Anti-SIV gag specific immune responses
were also assessed by Western blot utilizing HIV-2 anti-
gen (genetically similar to SIV) labeled strips, previously
shown to efficiently detect anti-SIV gag immune re-
sponses (Kent et al., 2001b).
Proliferation assays
Antigen-specific T cell proliferation assays were per-
formed postimmunization as described previously (Kent
et al., 1997, 1998, 2000). Antigens used for stimulation
were whole Aldrithiol-2 inactivated SIVmac239 and super-
natant from the SUPT1-CCR5 CL.30 cell line in which the
virus was grown as a negative control (10 g/ml; kindly
provided by the AIDS Vaccine Program, National Cancer
Institute, MD (Arthur et al., 1998)); SIVmac239 p55 gag pro-
tein 10 g/ml and VSV-N protein derived from similar
baculovirus cultures as a negative control; 3 g/ml HIV-1
tat peptide pool of 15-mer peptides overlapping by 11 aa;
and 3 g/ml HIV-1 rev peptide pool of 15-mer peptides
overlapping by 11 aa (obtained through the AIDS Re-
search and Reference Reagent Program, NIAID NIH).
PBMC were also activated with pokeweed mitogen (Sig-
ma) as a positive control for activation.
ELISPOT quantification of IFN production
ELISPOT assays were used to detect antigen specific
macaque IFN production following immunization ac-
cording to the manufacturer’s instructions (U-CyTech bv
diagnostics, Utrecht, The Netherlands) as previously de-
scribed (Dale et al., 2000; Kent et al., 2001b). Briefly,
96-well flat-bottom, transparent microtiter plates were
coated with 5 g (in 50 l) of anti-IFN mAb MD-1
(U-Cytech) and incubated overnight at 4°C. Plates were
washed five times with PBST (PBS containing 0.05%
Tween 20) to remove capture antibody and blocked with
PBS containing 1% BSA for 1 h at 37°C. A total of 5  105
batch thawed PBMC in RPMI medium  5% FCS were
cultured overnight separately in 48-well plates with an-
tigen (single SIV gag, HIV rev, or HIV tat 15-mer peptide
pools, overlapping by 11 aa, from the AIDS Research and
Reference Reagent Program, NIAID, NIH) or mitogen
(SEB, staphylococcal enterotoxin B, Sigma, Australia). A
total of 2 105 washed nonadherent cells (in 100 l) was
transferred to the ELISPOT plate in duplicate wells, in-
cubated for 5 h for expression and capture of IFN, and
then stored overnight at 4°C. The cells were then dis-
carded, and remaining cells were lysed with 200 ml/well
of ice-cold deionized water for 15 min and washed.
Captured cytokine was detected by 1 h incubation at
37°C with 1 g (in 100 l) of rabbit polyclonal, biotinyl-
ated anti-IFN (pAb, U-Cytech) and washed. A total of 50
l per well of an anti-biotin IgG gold conjugate (GABA,
U-Cytech) was added for 1 h at 37°C and spots were
developed. Spots were counted using an ELISPOT
reader (AID, Strassberg, Germany).
Intracellular detection of IFN cytokine secretion
Induction of SHIV-specific intracellular IFN expres-
sion in CD38 lymphocytes was assessed by flow
cytometry as previously described (Maecker et al., 2001).
Briefly, 200 l whole blood was incubated with 3 g/ml of
whole inactivated SIV, overlapping 15-mer SHIV peptide
sets (SIV-1 gag, HIV-1 tat, and HIV-1 rev, described
above), or control antigens and the costimulatory anti-
bodies CD28 and CD49d (BD Biosciences, PharMingen,
San Diego, CA) for 6 h. Brefeldin A (10 g/ml; Sigma) was
included during the last 4 h of the incubation. Anti-
CD3–PE and anti-CD8–PerCP (BD) were added to each
well and incubated for 30 min. Red blood cells were
lysed (FACS lysing solution, BD) and washed with PBS
and the remaining cells were permeabilized (Cytofix-
Cytoperm, BD). Permeabilized cells were then incubated
with anti-IFN–FITC antibody (Mabtech, Sweden) prior to
paraformaldehyde fixation and acquisition (FACScan,
BD). Acquisition data were analyzed using CellQuest
(BD). The percentage of antigen-specific gated lympho-
cytes expressing IFN was assessed in both total CD3
lymphocytes and the CD3CD8 subset.
SHIV challenge stock
SHIV229(mn) was a kind gift from Dr. Michael Agy (Univ. of
Washington). The SHIV229(mn) strain is based on SHIVIIIB
encoding HIV-1HXBc2 tat, rev, and env on a SIVmac239 back-
bone and was passaged throughM. nemestrina in vivo to
become pathogenic (Thompson et al., 2000). To generate
the challenge stock, SHIV229(mn) was expanded on PHA-
activatedM. nemestrina PBMC as follows: 1 107 PBMC
purified from each of 3 macaques were pooled and
activated with phytohemagglutinin (PHA 10 g/ml; Murex
Biotech Ltd.) and IL-2 (50 U/ml; Hoffmann–La Roche,
185HPV–SHIV VIRUS-LIKE-PARTICLE VACCINES
Nutley, NJ) for 3 days before being infected with
SHIV229(mn) at an m.o.i. of 0.1 TCID50/cell. This culture was
maintained by changing the culture medium every sec-
ond day. On day 7, the cells were pelleted and used to
infect a larger number of PHA/IL-2-activated M. nemes-
trina PBMC (3 108 PBMC pool from 14 macaques). The
infection was maintained for a further 10 days and the
supernatant was collected and titrated. The SHIV229(mn)
virus stock was 2  105 TCID50/ml on the CEM174 T
cell line.
Assessment of the challenge stock in four macaques
To assess the in vivo infectivity of the amplified
SHIV229(mn) challenge stock, four pigtailed macaques were
inoculated intrarectally as previously described (Kent et
al., 2001b). A similarly grown SHIV229(mn) stock was previ-
ously titrated by vaginal mucosal infection of M. nemes-
trina and was highly infectious (Thompson et al., 2000).
Two macaques were infected with 0.2 ml (4 104 TCID50)
and two with 1.0 ml (2  105 TCID50) using two equal
doses over 2 consecutive days and the SHIV infection
was followed over 5 weeks.
Immunized and control macaques were challenged
with this macaque–PBMC amplified SHIV229(mn) stock in-
trarectally using two 0.25 ml (105 TCID50 total) on 2
consecutive days.
CD4 T cell and SHIV RNA analyses
CD3 CD4 T lymphocyte populations were deter-
mined using FACS. A total of 200 l whole blood was
incubated with CD3–PE and CD4–FITC (anti-human
CD3–PE, anti-human CD4–FITC; BD PharMingen) anti-
bodies prior to lysis of red blood cells using FACS lysis
buffer (BD) as previously described (Kent et al., 2001b).
Cells were acquired using a BD FACSort and analyzed
using CellQuest (BD). RNA was extracted from plasma
separated from EDTA-anticoagulated blood using the
QIAamp viral RNA kit (Qiagen). SHIV viral RNA was
quantified using real-time PCR as previously described
(Jin et al., 1999; Kent et al., 2001b).
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